Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran

被引:9
作者
Maghzi, A. H. [1 ]
Etemadifar, M. [1 ]
Saadatnia, M. [1 ]
机构
[1] Isfahan Univ Med Sci, Sch Med, Dept Neurol, Esfahan, Iran
关键词
epidemiology; Iran; Isfahan; primary progressive multiple sclerosis;
D O I
10.1111/j.1468-1331.2007.01680.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Primary progressive multiple sclerosis (PPMS) is an uncommon form of multiple sclerosis (MS) in which the course of disease is progressive from onset. In a retrospective study amongst 1606 MS patients registered in Isfahan MS Society (IMSS) from April 2003 to 31 December 2005, 92 PPMS cases were identified. That means, the frequency of PPMS amongst all included MS patients would be 5.7% (95% CI: 6.7% and 4.7%). The mean expanded disability status scale (EDSS) for the group was 5.09 +/- 1.3. The commonest mode of presentation was motor disturbance in 55 (59.8%), other modes of presentation were, vertigo in 15 (16.3%), visual problems in 12 (13%), sensory disturbances in six (6.5%), and diplopia in four (4.3%). The current existing symptoms were motor problems in all 92 (100%), cerebellar symptoms in 46 (50%), and cognitive impairment in only six (6.5%). Interestingly, two (2%) were affected by poliomyelitis during childhood and presenting symptom in both was limb weakness. Primary progressive form of MS is less common in Persian population and some of the rates observed in PPMS patients differ from those in other regions, these differences may be due to different ethnicity of Persian patients or to geographical differences.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 40 条
[11]   The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment [J].
Fischer, JS ;
Rudick, RA ;
Cutter, GR ;
Reingold, SC .
MULTIPLE SCLEROSIS JOURNAL, 1999, 5 (04) :244-250
[12]   Soluble E-selectin in multiple sclerosis: Raised concentrations in patients with primary progressive disease [J].
Giovannoni, G ;
Thorpe, JW ;
Kidd, D ;
Kendall, BE ;
Moseley, IF ;
Thompson, AJ ;
Keir, G ;
Miller, DH ;
Feldmann, M ;
Thompson, EJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (01) :20-26
[13]   AN IMMUNOGENETIC HETEROGENEITY IN MULTIPLE-SCLEROSIS [J].
HILLERT, J ;
GRONNING, M ;
NYLAND, H ;
LINK, H ;
OLERUP, O .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (10) :887-890
[14]   Multiple sclerosis: report on 200 cases from Iran [J].
Kalanie, H ;
Gharagozli, K ;
Kalanie, AR .
MULTIPLE SCLEROSIS, 2003, 9 (01) :36-38
[15]   The natural history of multiple sclerosis: a geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation [J].
Kremenchutzky, M ;
Cottrell, D ;
Rice, G ;
Hader, W ;
Baskerville, J ;
Koopman, W ;
Ebers, GC .
BRAIN, 1999, 122 :1941-1949
[16]  
Kurtzke JF, 2000, J NEUROVIROL, V6, pS134
[17]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[18]  
LARSEN JP, 1985, ACTA NEUROL SCAND, V72, P145
[19]   CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL .3. CLINICAL COURSE + PROGNOSIS RELATED TO AGE AT ONSET [J].
LEIBOWITZ, U ;
HALPERN, L ;
ALTER, M .
NEUROLOGY, 1964, 14 (10) :926-&
[20]   Defining the clinical course of multiple sclerosis: Results of an international survey [J].
Lublin, FD ;
Reingold, SC .
NEUROLOGY, 1996, 46 (04) :907-911